The Biden Cancer Initiative is teaming up with nine healthcare companies to form a clinical trials information platform for patient matching and data mining.
The Oncology Clinical Trial Information Commons will include information relating to patient selection criteria, trial locations and patient participation requirements. Biopharma companies will also be able to enter and update their clinical trials on the platform.
The OCTIC platform will be available to clinical trial sponsors and investigators, government registry programs, patient advocacy organizations, health institutions and technology developers.
The program's founding members are BreastCancerTrials.org, Cancer Commons, Citizen, EmergingMed, GenomOncology, IBM Watson Health, Massive Bio, Quantum Leap Healthcare Collaborative, Genospace/Sarah Cannon Research Institute and Syapse.